LLY

753.95

+2.28%↑

JNJ

151.07

+1.12%↑

UNH

291.93

+7.04%↑

ABBV

183.3

+0.85%↑

NVO

64.06

-2.9%↓

LLY

753.95

+2.28%↑

JNJ

151.07

+1.12%↑

UNH

291.93

+7.04%↑

ABBV

183.3

+0.85%↑

NVO

64.06

-2.9%↓

LLY

753.95

+2.28%↑

JNJ

151.07

+1.12%↑

UNH

291.93

+7.04%↑

ABBV

183.3

+0.85%↑

NVO

64.06

-2.9%↓

LLY

753.95

+2.28%↑

JNJ

151.07

+1.12%↑

UNH

291.93

+7.04%↑

ABBV

183.3

+0.85%↑

NVO

64.06

-2.9%↓

LLY

753.95

+2.28%↑

JNJ

151.07

+1.12%↑

UNH

291.93

+7.04%↑

ABBV

183.3

+0.85%↑

NVO

64.06

-2.9%↓

Search

Catalyst Pharmaceuticals Inc

Chiusa

SettoreSettore sanitario

23.73 1.32

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

23.19

Massimo

23.93

Metriche Chiave

By Trading Economics

Entrata

801K

57M

Vendite

-399K

141M

P/E

Media del settore

18.191

56.602

EPS

0.68

Margine di Profitto

40.119

Dipendenti

181

EBITDA

526K

73M

Raccomandazioni

By TipRanks

Raccomandazioni

Fortemente da comprare

Previsioni per 12 mesi

+45.3% upside

Dividendi

By Dow Jones

Utili prossimi

6 ago 2025

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

-123M

2.9B

Apertura precedente

22.41

Chiusura precedente

23.73

Notizie sul Sentiment di mercato

By Acuity

26%

74%

59 / 382 Classifica in Healthcare

Punteggio Tecnico

By Trading Central

Fiducia

Bearish Evidence

Catalyst Pharmaceuticals Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

15 mag 2025, 22:52 UTC

Utili
I principali Market Mover

Virgin Galactic Shares Rise on Commercial Spaceflight Plans, Narrower 1Q Loss

15 mag 2025, 20:37 UTC

Notizie principali
Utili

Applied Materials Logs Higher 2Q Profit, Revenue as Customer Demand Remains Unchanged

16 mag 2025, 00:00 UTC

Discorsi di Mercato

Xero Bull Stays Positive on Cost Outlook -- Market Talk

15 mag 2025, 23:47 UTC

Discorsi di Mercato

Gold Consolidates; Likely Supported by Signs of Disinflation -- Market Talk

15 mag 2025, 23:38 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

15 mag 2025, 23:38 UTC

Discorsi di Mercato

Nikkei May Edge Higher, Tracking Gains Across Most U.S. Equity Markets -- Market Talk

15 mag 2025, 23:14 UTC

Notizie principali

Walmart Becomes Biggest Retailer Yet to Pass Through Tariff Price Increases -- 4th Update

15 mag 2025, 22:46 UTC

Notizie principali
Acquisizioni, Fusioni, Takeovers

Bayer Seeks New Roundup Settlement While Exploring Monsanto Bankruptcy -- WSJ

15 mag 2025, 22:46 UTC

Acquisizioni, Fusioni, Takeovers

Bayer Working With Restructuring Advisers Latham, AlixPartners to Explore Options for Monsanto -- WSJ

15 mag 2025, 22:46 UTC

Acquisizioni, Fusioni, Takeovers

Bayer Exec Says Company Committed to Resolving Roundup Lawsuits in 18 Months -- WSJ

15 mag 2025, 22:46 UTC

Acquisizioni, Fusioni, Takeovers

Bayer Seeks New Roundup Settlement While Exploring Monsanto Bankruptcy -- WSJ

15 mag 2025, 21:58 UTC

Utili

Applied Materials Earnings Beat Expectations. Why the Stock Is Down. -- Barrons.com

15 mag 2025, 21:24 UTC

Utili

Cava's Earnings Beat Expectations. Growth Was Strong Despite Tariff Fears. -- Barrons.com

15 mag 2025, 20:56 UTC

Discorsi di Mercato

U.S. Spending Downturn Could Lie Ahead -- Market Talk

15 mag 2025, 20:54 UTC

Discorsi di Mercato
Utili

Applied Materials CFO Says Demand Stable Despite Tariffs, Macro -- Market Talk

15 mag 2025, 20:54 UTC

Utili

Applied Materials Investing to Support Semiconductor Market of More Than $1T by End of Decade, Financial Chief Says

15 mag 2025, 20:51 UTC

Utili

Applied Materials Financial Chief: Long-Term Secular Growth Drivers Remain Intact

15 mag 2025, 20:50 UTC

Discorsi di Mercato

Financial Services Roundup: Market Talk

15 mag 2025, 20:50 UTC

Acquisizioni, Fusioni, Takeovers

Berkshire Sells Financial Stocks, Doubles Constellation Stake, Holds Steady on Apple -- WSJ

15 mag 2025, 20:50 UTC

Utili

Applied Materials' Customer Investments Continue at Expected Rate and Pace, Financial Chief Says

15 mag 2025, 20:47 UTC

Utili

Applied Materials Not Currently Seeing Large Changes in Customer Demand, CEO Says

15 mag 2025, 20:47 UTC

Utili

Applied Materials Sees Revenue From Advanced DRAM Customers to Grow 40% in FY25, CEO Says

15 mag 2025, 20:47 UTC

Utili

Applied Materials Grew Faster Than Peers in Markets Outside China in 2Q, CEO Says

15 mag 2025, 20:47 UTC

Utili

Applied Materials Underperformed Market in China in 2Q Due to Restrictions on U.S. Companies, CEO Says

15 mag 2025, 20:37 UTC

Utili

SOS Ltd: Growth Was Fueled by Robust Domestic Demand and Expansion of Pdt Portfolio to Include Rubber and Coal >SOS

15 mag 2025, 20:37 UTC

Utili

SOS Ltd: Cryptocurrency Mining Rev Declined to $9.3M From $18.9M in FY23, Dip Was Attributed to the Temporary Shutdown of Texas Mining Facility for Upgrades During 1H 2024 >SOS

15 mag 2025, 20:37 UTC

Utili

SOS Ltd: FY24 Significant Yr-over-Yr Increase in Commodity Trading Rev, Which Soared to $214.3M FY24, 92.6% of Total Rev Up From 74.0% in FY23 >SOS

15 mag 2025, 20:37 UTC

Utili

SOS Ltd: Cryptocurrency Mining Rev Halves as SOS Focuses on Facility Upgrades and Commodity Expansion >SOS

15 mag 2025, 20:26 UTC

Notizie principali

Trump Presses Apple to Bring iPhone Manufacturing to America. Wall Street Shrugs. -- WSJ

15 mag 2025, 20:25 UTC

Utili

Deere Stock Jumps on Guidance Cut. Here's Why. -- Barrons.com

Confronto tra pari

Modifica del prezzo

Catalyst Pharmaceuticals Inc Previsione

Obiettivo di Prezzo

By TipRanks

45.3% in crescita

Previsioni per 12 mesi

Media 34 USD  45.3%

Alto 40 USD

Basso 31 USD

Basato su 7 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Catalyst Pharmaceuticals Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

7 ratings

7

Acquista

0

Mantieni

0

Vendi

Punteggio Tecnico

By Trading Central

N/A / 24.28Supporto e resistenza

A breve termine

Bearish Evidence

A termine intermedio

Bullish Evidence

A lungo termine

Bullish Evidence

Sentiment

By Acuity

59 / 382 Classifica in Settore sanitario

Notizie sul Sentiment di mercato

Prove rialziste

Volatilità

Sotto la media

Volume delle notizie (RCV)

Sopra la media

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Catalyst Pharmaceuticals Inc

Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis and spinal muscular atrophy type. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was founded in 2002 and is based in Coral Gables, Florida.